Biotech Spotlight: Aurina Pharmaceuticals Inc, SCYNEXIS Inc, and The Medicines Company

Among the drugmakers in focus are Aurina Pharmaceuticals Inc (NASDAQ:AUPH), SCYNEXIS INc (NASDAQ:SCYX), and The Medicines Company (NASDAQ:MDCO)

Oct 6, 2016 at 11:12 AM
facebook twitter linkedin


A handful of biotech stocks are making big moves today. Among the drugmakers in focus are Aurina Pharmaceuticals Inc (NASDAQ:AUPH), SCYNEXIS Inc (NASDAQ:SCYX), and The Medicines Company (NASDAQ:MDCO).

  • AUPH is the best-performing Nasdaq stock thus far, up 31.6% at $5.33, after the company reported encouraging data for Voclosporin, its lead treatment for lupus nephritis. The shares of AUPH have officially closed their August bear gap -- triggered by concerns of patient deaths related to the aforementioned drug -- to touch a fresh multi-year high of $5.69 earlier. A few recent short sellers could be kicking rocks, as short interest on Aurina Pharmaceuticals Inc skyrocketed more than 300% during the past two reporting periods.

  • SCYX is 4.8% higher at $5.03, after the firm unveiled the results of two Phase 2 studies and said it closed a $15 million term loan with Solar Capital Ltd. (NASDAQ:SLRC). The stock has rocketed 189% since touching a record low of $1.74 in mid-July, and is on pace to topple its 50-week moving average for the first time in more than a year. Analysts are already in SCYNEXIS Inc's corner, though, with all four covering brokerage firms doling out "buy" or better endorsements.
  • MDCO is down 13.8% at $33.18, as Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) -- with which it's developing a cholesterol-lowering drug -- gets destroyed. The Medicines Company shares are now south of their 80-day moving average for the first time since late July, landing on the short-sale restricted list. Still, there are likely quite a few shorts cheering today, as more than 19% of MDCO's float is dedicated to short interest. At the stock's average pace of trading, it would take more than three weeks to buy back these bearish bets.

Sign up now for Schaeffer's Market Recap to get all the day's big stock movers, must-know technical levels, and top economic stories straight to your inbox.
 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Master Portfolio Trial
 


 


 
Special Offers from Schaeffer's Trading Partners